Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $
Biotechnology, Pharmaceuticals, Health
2026-06-17 5:22 PM EDT | Hemostemix Inc.
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, an
Biotechnology, Pharmaceuticals, Health
2026-06-17 3:15 AM EDT | Defence Therapeutics Inc.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Telescope Innovations Provides Financial Results of Third Fiscal Quarter 2026
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE:J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended May 31, 2026 (Q3 FY2026). The Company generated revenues of approximately $2.1 million during this period, driven by a combination of contract services and Self-D
Technology, Chemical, Pharmaceuticals
2026-06-16 8:00 AM EDT | Telescope Innovations Corp.
Herbal Dispatch Provides Update on Domestic Retail Operations and Proprietary Brand Expansion
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, is pleased to provide an update on the continued growth of its domestic retail operations and expanding portfolio of proprietary cannabis brands. As part of its strategy to increase exposure to higher-margin branded products and build lon
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-06-16 3:01 AM EDT | Herbal Dispatch Inc.
Extendicare Announces June 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - June 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of June 2026, which is payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare i
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 8:00 AM EDT | Extendicare Inc.
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery. PTSD affects veterans, first responde
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-15 7:00 AM EDT | Cannabis Bioscience International Holdings
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 7:00 AM EDT | Elite Pharmaceuticals, Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units
Biotechnology, Pharmaceuticals, Health
2026-06-12 5:39 PM EDT | PreveCeutical Medical Inc.
Bachem Holding AG Announces Capital Markets Day 2026
Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, as well as virtually. This hybrid event will provide insights into the company's strategic priorities, business outlook, and key developments.
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-06-12 11:47 AM EDT | Bachem Holding AG
Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equity interest in CWE European Holdings Inc. ("CWE") not already owned by the Company, through a series of ancillary transa
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-12 7:30 AM EDT | Neural Therapeutics Inc.
Telescope Innovations to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to announce it will be presenting at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17th, 2026. At Planet MicroCap, Dr. Jeffrey Sherman will provide an update on Telesc
Technology, Chemical, Pharmaceuticals
2026-06-11 8:00 AM EDT | Telescope Innovations Corp.
Custom Health Announces Closing of the Acquisition of InnovativeRx Operating Subsidiaries to Expand Integrated Medication Management Infrastructure Across North America
Strategic Acquisition: Custom Health announces the closing of the acquisition of substantially all of the operating assets of InnovativeRx US Holdings, Inc. ("InnovativeRx") to expand its integrated healthcare infrastructure across North America. InnovativeRx is an existing operational partner already utilizing Custom Health's proprietary AdhereNet® platform, enabling streamlined integration and workflow continuity. F
Technology, Pharmaceuticals, Health
2026-06-10 7:00 AM EDT | Custom Health Holdings Inc.
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-09 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Gaithersburg, Maryland--(Newsfile Corp. - June 9, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, and United Dogecoin, Inc., Shuttle Pharma's wholly owned subsidiary and a Dogecoin mining company, today announced that its board of directors have approved a proposed reverse stock split of its common stock at a
2026-06-09 8:30 AM EDT | Shuttle Pharmaceuticals Holdings Inc.
Herbal Dispatch Completes 452kg Multi Client Medical Cannabis Export Shipment To Europe
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, is pleased to announce the successful completion of a 452-kilogram international medical cannabis export shipment to several customers in Germany. While the shipment represents an important operational milestone, its gr
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-06-09 3:01 AM EDT | Herbal Dispatch Inc.
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchisi
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-08 7:00 AM EDT | Cannabis Bioscience International Holdings
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effectiv
Biotechnology, Pharmaceuticals, Health
2026-06-08 3:00 AM EDT | PreveCeutical Medical Inc.
Custom Health Holdings Inc. Announces Completion of Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Custom Health Holdings Inc. (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated May 13, 2026, is pleased to announce the successful completion of its previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") with Custom Health, Inc. ("Custom Delaware"), pursuant to which, among other thing
Technology, Pharmaceuticals, Health
2026-06-05 6:00 PM EDT | Custom Health Holdings Inc.
Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") congratulates its Founder and Chief Technology Officer, Professor Jason Hein, on receiving the 2026 SCI Canada LeSueur Memorial Award from the Society of Chemical Industry ("SCI").
Technology, Chemical, Pharmaceuticals
2026-06-05 8:00 AM EDT | Telescope Innovations Corp.